IPO registrations (S-1, F-1) · Registrants
CytoDyn Inc.
- SEC CIK
- 1175680 · filings on EDGAR ↗
- Former names
- CYTODYN INC (2003–2016); REXRAY CORP (2002–2003)
- Registration
- Form S-1, first filed 2013-11-15, last 2026-04-22; 8 initial registrations, 4 amendments
- Outcome
- Declared effective 2014-02-05; withdrawal requested 2022-09-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1111 MAIN STREET, SUITE 660, Vancouver, WA 98660
- EIN
- 75-3056237
- Ticker
- CYDY (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CytoDyn Inc. on the corporate pages
On this site
- Business registration: CYTODYN INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CYTODYN OPERATIONS INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CYTODYN INC. Fuzzy (name and state)
- Form 5500 plan sponsor: CYTODYN INC EXACT (EIN (EXACT))
- Form D issuer: CytoDyn Inc. EXACT (CIK (EXACT))
- SEC filer: CytoDyn Inc. EXACT (CIK (EXACT))
- Person page: Alan P Timmins Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 55
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-11-15 | S-1 | S-1 (registration) | CYTODYN INC | 0001193125-13-443821 ↗ |
| 2014-01-31 | S-1/A | S-1/A (amendment) | CYTODYN INC | 0001193125-14-030551 ↗ |
| 2014-02-05 | EFFECT | EFFECT (declared effective) | CYTODYN INC | 9999999995-14-000324 ↗ |
| 2015-06-08 | S-1 | S-1 (registration) | CYTODYN INC | 0001193125-15-216414 ↗ |
| 2015-08-20 | S-1/A | S-1/A (amendment) | CYTODYN INC | 0001193125-15-296581 ↗ |
| 2015-09-02 | S-1/A | S-1/A (amendment) | CYTODYN INC | 0001193125-15-309690 ↗ |
| 2015-09-02 | EFFECT | EFFECT (declared effective) | CYTODYN INC | 9999999995-15-002423 ↗ |
| 2015-09-02 | EFFECT | EFFECT (declared effective) | CYTODYN INC | 9999999995-15-002427 ↗ |
| 2015-09-11 | S-1 | S-1 (registration) | CYTODYN INC | 0001193125-15-318527 ↗ |
| 2015-10-01 | S-1/A | S-1/A (amendment) | CYTODYN INC | 0001193125-15-335514 ↗ |
| 2015-10-05 | EFFECT | EFFECT (declared effective) | CYTODYN INC | 9999999995-15-002662 ↗ |
| 2016-02-03 | S-1 | S-1 (registration) | CYTODYN INC | 0001193125-16-448171 ↗ |
| 2016-02-17 | EFFECT | EFFECT (declared effective) | CYTODYN INC | 9999999995-16-003794 ↗ |
| 2016-09-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-16-005659 ↗ |
| 2016-10-21 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-16-006050 ↗ |
| 2018-03-07 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-18-000551 ↗ |
| 2018-03-23 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-18-000667 ↗ |
| 2018-11-28 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-18-002985 ↗ |
| 2018-11-28 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-18-002986 ↗ |
| 2018-11-28 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-18-002987 ↗ |
| 2019-02-14 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-19-000265 ↗ |
| 2019-09-30 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-19-002213 ↗ |
| 2020-05-11 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-20-001113 ↗ |
| 2020-09-25 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-20-002582 ↗ |
| 2020-12-30 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-20-003711 ↗ |
| 2021-01-22 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-21-000252 ↗ |
| 2021-10-06 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-21-003797 ↗ |
| 2022-09-02 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-22-002579 ↗ |
| 2022-09-26 | RW | RW (withdrawal request) | CytoDyn Inc. | 0001558370-22-014616 ↗ |
| 2022-09-30 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-22-002886 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000336 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000337 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000338 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000339 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000340 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000341 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000342 ↗ |
| 2023-02-09 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-000343 ↗ |
| 2023-06-21 | S-1 | S-1 (registration) | CytoDyn Inc. | 0001104659-23-073406 ↗ |
| 2023-07-10 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-002040 ↗ |
| 2023-10-05 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-23-002938 ↗ |
| 2024-02-07 | S-1 | S-1 (registration) | CytoDyn Inc. | 0001558370-24-000836 ↗ |
| 2024-02-21 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-24-000513 ↗ |
| 2024-09-09 | S-1 | S-1 (registration) | CytoDyn Inc. | 0001558370-24-012660 ↗ |
| 2024-09-12 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-24-002805 ↗ |
| 2024-09-12 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-24-002807 ↗ |
| 2024-10-01 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-24-003058 ↗ |
| 2025-08-21 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-25-002703 ↗ |
| 2025-12-02 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-25-003478 ↗ |
| 2025-12-16 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-25-003778 ↗ |
| 2026-04-22 | S-1 | S-1 (registration) | CytoDyn Inc. | 0001104659-26-046921 ↗ |
| 2026-05-20 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-26-001716 ↗ |
| 2026-10-02 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-26-003138 ↗ |
| 2026-10-02 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-26-003140 ↗ |
| 2026-10-07 | EFFECT | EFFECT (declared effective) | CytoDyn Inc. | 9999999995-26-003176 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Gould Gregory A | Director | 22 | 2006–2019 | ||
| Leong Jonathan R | Director | 1 | 2006 | ||
| UTEK CORP | TenPercentOwner | 2 | 2006–2009 | ||
| ALLEN CORINNE E | Director,Officer,TenPercentOwner | Chief Financial Officer; Vice President | 8 | 2007–2010 | |
| ALLEN ALLEN D | Director,Officer,TenPercentOwner | Chief Executive Officer | 6 | 2007–2009 | |
| Dembow George F | Director | 12 | 2008–2012 | ||
| Naydenov Jordan G | Director; Director,TenPercentOwner | 40 | 2009–2021 | ||
| Van Ness Kenneth | Director; Director,Officer; Director,Officer,TenPercentOwner; TenPercentOwner | CEO & President; President; President & CEO | 7 | 2010–2012 | |
| Tropp Ronald J | Director | 6 | 2011–2012 | ||
| Libby Andrew T. Jr. | Officer | Chief Financial Officer | 1 | 2011 | |
| Pourhassan Nader | Director,Officer; Officer | Chief Operating Officer; Interim President & CE0; Interim President & CEO; President and CEO; President & CEO | 37 | 2011–2021 | |
| Caracciolo Anthony | Director; Director,Officer | Executive Chairman | 28 | 2011–2019 | |
| Trauger Richard | Director; Director,Officer; Officer | Chief Scientific Officer | 3 | 2012–2013 | |
| Mulholland Michael D. | Officer | CFO, Treasurer and Secretary; Chief Financial Officer; See Remarks; SVP-Finance | 26 | 2012–2020 | |
| Nobel Michael | Director | 6 | 2012–2015 | ||
| GREEN ALLAN M | Director | 3 | 2012–2013 | ||
| Montgomery Alan Bruce | Director | 10 | 2013–2018 | ||
| BURGER DENIS R | Director | 12 | 2014–2018 | ||
| DOCKERY CARL | Director; Director,TenPercentOwner | 20 | 2014–2019 | ||
| ALPHA ADVISORS, LLC | TenPercentOwnerOther | 2 | 2015 | ||
| Alpha Venture Capital Partners, L.P. | TenPercentOwner | 2 | 2015 | ||
| Kelly Scott A. | Director; Director,Officer; Officer | Chairman & CMO; Chief Medical Officer; CMO | 36 | 2017–2022 | |
| Klump Michael A | Director | 10 | 2018–2020 | ||
| Pestell Richard MD | Director,Officer | Chief Medical Officer | 2 | 2018 | |
| Ray Nitya G. | Officer | Chief Technology Officer; See Remarks | 19 | 2018–2022 | |
| Welch David F | Director | 14 | 2019–2020 | ||
| Eastwood Craig S. | Officer | Chief Financial Officer | 3 | 2019–2020 | |
| Fleming Maura | Officer | See Remarks | 2 | 2020 | |
| TIMMINS ALAN P | Director | 6 | 2020–2021 | person page Fuzzy | |
| Colachis Arian | Officer | GC and Corporate Secretary | 4 | 2020 | |
| Patel Samir Rashmikant | Director | 7 | 2020–2021 | ||
| Rahman Mahboob U | Officer | Chief Scientific Officer | 2 | 2020 | |
| Recknor Chris P | Officer | Chief Operating Officer; See Remarks | 3 | 2021–2022 | |
| Migliarese Antonio | Officer | CFO; CFO & Interim President; Chief Financial Officer | 17 | 2021–2024 | |
| Gardiner Gordon A | Director | 4 | 2021 | ||
| Ndhlovu Lishomwa C | Director | 5 | 2021–2026 | ||
| Seethamraju Harish | Director | 1 | 2021 | ||
| Urbach Tanya Durkee | Director | 5 | 2021–2026 | ||
| Brunke Karen J | Director | 5 | 2022–2026 | ||
| Arman Arvin Cyrus | Officer | President | 3 | 2022–2023 | |
| Dunlap Ryan | Director | 5 | 2022–2026 | ||
| SIMES STEPHEN M | Director | 5 | 2022–2026 | ||
| Blok Tyler | Officer | Chief Legal Officer; EVP of Legal Affairs | 4 | 2023–2026 | |
| Lalezari Jacob P | Officer | Chief Executive Officer; Interim CEO | 4 | 2023–2026 | |
| COHEN MITCHELL | Officer | Interim CFO | 1 | 2024 | |
| Hoffman Robert E. | Officer | Chief Financial Officer | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-05-11 | CytoDyn Inc. | Pharmaceuticals | $18,600,392 | $18,600,392 | 194 | 1 |
| 2022-04-22 | CytoDyn Inc. | Pharmaceuticals | $21,771,535 | $21,771,535 | 166 | 3 |
| 2021-12-03 | CytoDyn Inc. | Biotechnology | $53,593,700 | $11,361,000 | 118 | 1 |
| 2021-09-16 | CytoDyn Inc. | Biotechnology | $25,220,000 | $2,872,000 | 6 | 1 |
| 2020-12-16 | CytoDyn Inc. | Biotechnology | $1,176,000 | $0 | 0 | 1 |
| 2020-12-16 | CytoDyn Inc. | Biotechnology | $1,000,000 | $1,000,000 | 1 | 1 |
| 2020-03-30 | CytoDyn Inc. | Biotechnology | $1,157,625 | $882,000 | 1 | 1 |
| 2020-02-14 | CytoDyn Inc. | Biotechnology | $11,355,000 | $7,570,000 | 3 | 2 |
| 2019-04-02 | CytoDyn Inc. | Biotechnology | $20,000,000 | $7,788,000 | 61 | 2 |
| 2018-09-10 | CytoDyn Inc. | Biotechnology | $25,000,000 | $13,199,385 | 119 | 1 |
| 2017-11-16 | CytoDyn Inc. | Biotechnology | $17,643,452 | $17,643,452 | 200 | 2 |
| 2017-06-14 | CytoDyn Inc. | Biotechnology | $15,000,000 | $1,150,000 | 2 | 1 |
| 2016-05-11 | CytoDyn Inc. | Biotechnology | $10,000,000 | $4,301,500 | 41 | 1 |
| 2015-10-05 | CYTODYN INC | Biotechnology | $3,981,050 | $2,693,800 | 67 | 1 |
| 2015-07-14 | CYTODYN INC | Biotechnology | $33,268,465 | $33,268,465 | 261 | 2 |
| 2015-05-14 | CYTODYN INC | Biotechnology | $4,000,000 | $3,281,050 | 54 | 1 |
| 2012-01-17 | CYTODYN INC | Biotechnology | $3,000,000 | $2,996,082 | 86 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.